Trial Outcomes & Findings for Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) (NCT NCT01402531)

NCT ID: NCT01402531

Last Updated: 2019-12-04

Results Overview

The Investigator of this study passed away and we do not have the study data to upload the results.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 10 participants
• Primary outcome timeframe: 2 years
• Results posted on: 2019-12-04

Participant Flow

The Investigator of this study passed away and we do not have the study data to upload the results.

Participant milestones

Measure	Submucosal Bevacizumab 200mg Bevacizumab, submucosal injection Submucosal Bevacizumab: 200 mg Bevacizumab, injected submucosally- 100 mg per nostril
Overall Study STARTED	0
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 2 years

Population: The Investigator of this study passed away and we do not have the study data to upload the results.

The Investigator of this study passed away and we do not have the study data to upload the results.

Outcome measures

Outcome data not reported

Adverse Events

No Participants

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Department of Surgery

UCSD

Phone: (858) 657-5291

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place